Mylotarg Articles
Pfizer withdraws leukemia drug Mylotarg from US Market on safety concerns and poor efficacy
22 June 2010
Wyeth in talks to acquire Crucell; sources say potential offer could be up to $1.35B
12 January 2009
Toricel gets CHMP nod as first-line RCC drug
1 October 2007
Zeltia's Yondelis enters Phase III
9 April 2007
Israeli basket update c'tee recommends another 16 new technologies
4 September 2006
Wyeth increases stake in Wyeth KK
17 April 2006
Japanese OK for Wyeth's Mylotarg
8 August 2005
Wyeth oncology researchers honored
30 August 2004
Wyeth to boost sales 60% in Japan with new drug launches
22 September 2003
Celltech: new product pipeline
19 March 2001
Celltech profits up 28% ex-restructuring
14 March 2001
Antisense leukemia drug enters trials
22 January 2001
Oxford Bio licenses cancer drug to AHP
22 January 2001
Healthy harvest of New Chemical Entities in 2000
2 January 2001
Wyeth-Ayerst wins orphan drug status for Mylotarg in Europe
16 November 2000
Mylotarg effective in younger AML patients
16 October 2000
Celltech Group moves into the black
13 September 2000
Stock Commentary Europe
8 June 2000
Stock Commentary New York
25 May 2000
Celltech recommended by Goldman Sachs
28 March 2000
Stock Commentary Europe
23 March 2000
Goldman Sachs analysts upgrade Celltech
1 March 2000
Stock Commentary Europe
13 January 2000
Showing 1-33 of 33 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
